The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s pharmaceutical regulatory authority, have announced a new liaison program to establish dedicated, reciprocal liaison officer roles within each organization. The roles aim to enhance day-to-day collaboration, support scientific exchange, and enable faster, more coordinated approaches to emerging regulatory challenges and decisions.   

The initiative formalizes and increases cooperation between the two agencies across focus areas, including innovative medicines, medical devices, and emerging technologies such as AI. The liaison program is designed to support closer working across technical, policy, and scientific teams and provide new opportunities for joint initiatives, shared learning, and coordinated approaches to regulatory issues.  

Source: The UK Medicines and Healthcare products Regulatory Agency